Aeterna Zentaris Slides on Perifosine Miss in Myeloma
By Staff Reports
Monday, March 11, 2013
Shares of Aeterna Zentaris dropped 22.5 percent Monday after a data safety monitoring board (DSMB) said it was unlikely a Phase III study testing PI3/Akt inhibitor perifosine in multiple myeloma would hit its endpoints.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.